Inhibikase
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Inhibikase and other ETFs, options, and stocks.About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases.
IKT Key Statistics
Stock Snapshot
With a market cap of 261.43M, Inhibikase(IKT) trades at $1.98. The stock has a price-to-earnings ratio of -3.94.
On 2026-05-05, Inhibikase(IKT) stock traded between a low of $1.96 and a high of $1.99. Shares are currently priced at $1.98, which is +1.0% above the low and -0.5% below the high.
The Inhibikase(IKT)'s current trading volume is 100.4K, compared to an average daily volume of 882.65K.
In the last year, Inhibikase(IKT) shares hit a 52-week high of $2.30 and a 52-week low of $1.33.
In the last year, Inhibikase(IKT) shares hit a 52-week high of $2.30 and a 52-week low of $1.33.
Analyst ratings
100%
of 7 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.